Sign in

    Alexander Veytsman • B. Riley Securities, Inc.

    Alexander Veytsman is an equity research analyst most recently associated with B. Riley Securities, Inc., where he specialized in detailed company coverage within the consumer, retail, and wellness sectors. He has covered companies including WW International (Weight Watchers), Medifast, and Celsius Holdings, producing investment recommendations tracked by third-party platforms like TipRanks, which report his success rate at around 48% and an average return per rating of approximately 7%. Veytsman’s career in securities research began in the mid-2010s, with prior experience at firms such as Seeking Alpha, and he joined B. Riley Securities subsequently as an analyst. He holds active securities licenses, including Series 7 and Series 63, and has been recognized in industry databases such as FINRA BrokerCheck for compliance and professional credentials.

    Alexander Veytsman's questions to Paysign Inc (PAYS) leadership

    Alexander Veytsman's questions to Paysign Inc (PAYS) leadership • Q1 2025

    Question

    Alexander Veytsman from B. Riley Securities, Inc. asked about the expected duration of the headwinds in the plasma business and how the Gamma Innovation acquisition will help mitigate these challenges and drive future growth.

    Answer

    President and CEO Mark Newcomer acknowledged that headwinds from plasma supply surpluses are expected to persist through 2025. He explained the Gamma acquisition is a strategic move to strengthen their tech stack with a donor engagement app and CRM, creating an integrated platform to expand their addressable market. CFO Jeff Baker added the acquisition is expected to generate $4 million to $5 million in annual cash flow savings.

    Ask Fintool Equity Research AI